The thalidomide saga

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works

Thalidomide is an inhibitor of angiogenesis.

D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454 · see citing works

Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor Occupancy

Mueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,501 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

Integrin function: molecular hierarchies of cytoskeletal and signaling molecules.

Miyamoto, S., Teramoto, H., Coso, O. A., Gutkind, J. S., Burbelo, P. D., Akiyama, S. K., & Yamada, K. M. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.3.791 · Cited by 1,202 · see citing works

THALIDOMIDE AND CONGENITAL ABNORMALITIES

Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141 · see citing works

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,041 · see citing works

Efficacy of Lenalidomide in Myelodysplastic Syndromes

List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880 · see citing works

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · see citing works

The evolution of thalidomide and its IMiD derivatives as anticancer agents

Bartlett, J. B., Dredge, K. S., & Dalgleish, A. G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1323 · Cited by 811 · see citing works

Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity

Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760 · see citing works

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729 · see citing works

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669 · see citing works

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

Attal, M., Harousseau, J., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub‐Agha, I., Bourhis, J.-H., Garderet, L., Pegourié, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 663 · see citing works

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 654 · see citing works

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

Haslett, P. A. J., Corral, L. G., Albert, M. L., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 572 · see citing works

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.-T., Lin, B. K., Lentzsch, S., Davies, F. E., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 554 · see citing works

Thalidomide in the treatment of lepra reactions

Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 534 · see citing works

CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells

Qin, Z., & Blankenstein, T. J. F. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511 · see citing works

Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity

Keifer, J. A., D, D. C. G., Ashburner, B. P., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 477 · see citing works

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

Hamuryudan, V., Mat, C., Saip, S., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-6-199803150-00004 · Cited by 457 · see citing works

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

Wolkenstein, P., Latarjet, J., Roujeau, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 430 · see citing works

Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection

Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362103 · Cited by 411 · see citing works

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

Sampaio, E. P., Kaplan, G., Miranda, A., et al. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 370 · see citing works

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

Bellamy, W. T., Richter, L. C., Sirjani, D., Roxas, C., Glinsmann‐Gibson, B., Frutiger, Y. M., Grogan, T. M., & List, A. F. (2001) · Blood · doi:10.1182/blood.v97.5.1427 · Cited by 342 · see citing works

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312 · see citing works

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes

Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J. M., et al. (2001) · Blood · doi:10.1182/blood.v98.4.958 · Cited by 304 · see citing works

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

Dredge, K. S., Marriott, J. B., Macdonald, C., Man, H., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 297 · see citing works

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Dredge, K. S., Horsfall, R., Robinson, S. P., Zhang, L., Lu, L., Tang, Y., Shirley, M. A., Muller, G. W., Schafer, P. H., Stirling, D., et al. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.01.002 · Cited by 268 · see citing works

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

McHugh, S., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 262 · see citing works

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

Glasmacher, A. G., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K. S., Schmidt‐Wolf, I. G. H., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237 · see citing works

Lenalidomide and Venous Thrombosis in Multiple Myeloma

Knight, R., DeLap, R. J., & Zeldis, J. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053530 · Cited by 234 · see citing works

The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma

Baz, R., Li, L., Kottke‐Marchant, K., Srkalović, G., McGowan, B. R., Yiannaki, E. O., Karam, M. A., Faiman, B. M., Jawde, R. M. A., Andresen, S. W., et al. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1568 · Cited by 228 · see citing works

S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide

Zeldis, J. B., Williams, B. A., Thomas, S. D., & Elsayed, M. E. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88289-2 · Cited by 223 · see citing works

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

Fabro, S. E., Smith, R. L., & Williams, R. T. (1967) · Nature · doi:10.1038/215296a0 · Cited by 200 · see citing works

IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ

Beatty, G. L., & Paterson, Y. Y. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2276 · Cited by 195 · see citing works

Thalidomide as salvage therapy for chronic graft-versus-host disease

Parker, P., Chao, N. J. A., Nademanee, A., et al. (1995) · Blood · doi:10.1182/blood.v86.9.3604.bloodjournal8693604 · Cited by 193 · see citing works

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

Lee, C., Barlogie, B., Munshi, N. C., Zangari, M., Fassas, A., Jacobson, J. L., van Rhee, F., Cottler‐Fox, M., Muwalla, F., & Tricot, G. J. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175 · see citing works

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

Dredge, K. S., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 163 · see citing works

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

Lentzsch, S., LeBlanc, R., Podar, K., Davies, F. E., Lin, B. K., Hideshima, T., Catley, L. P., Stirling, D., & Anderson, K. C. (2003) · Leukemia · doi:10.1038/sj.leu.2402745 · Cited by 162 · see citing works

Thalidomide and its analogues have distinct and opposing effects on TNF-αand TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

Marriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155 · see citing works

Thalidomide and Congenital Abnormalities

McBride, W. G. (1961) · Springer eBooks · doi:10.1007/978-94-011-6621-8_27 · Cited by 142 · see citing works

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

Bartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 141 · see citing works

Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.

Chen, T., Vogelsang, G. B., Petty, B. G., Brundrett, R. B., Noe, D. A., Santos, G. W., & Colvin, O. M. (1989) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07646-9 · Cited by 122 · see citing works

Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Kyriakou, C. A., Thomson, K. J., D’Sa, S., Flory, A. J., Hanslip, J., Goldstone, A. H., & Yong, K. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05521.x · Cited by 115 · see citing works

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

Tosi, P., Zamagni, E., Cellini, C., Cangini, D., Tacchetti, P., Tura, S., Baccarani, M., & Cavo, M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00272.x · Cited by 112 · see citing works

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes

Zorat, F., Shetty, V. T., Dutt, D., Lisak, L., Nascimben, F., Allampallam, K., Dar, S., York, A., Gezer, S., Venugopal, P., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03204.x · Cited by 108 · see citing works

Intravenous Formulations of the Enantiomers of Thalidomide: Pharmacokinetic and Initial Pharmacodynamic Characterization in Man

Eriksson, T., Björkman, S. E., Roth, B., & Höglund, P. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774660 · Cited by 94 · see citing works

Thalidomide and a Thalidomide Analogue Drug Costimulate Virus‐Specific CD8+T Cells In Vitro

Haslett, P. A. J., Hanekom, W. A., Muller, G. W., & Kaplan, G. (2003) · The Journal of Infectious Diseases · doi:10.1086/368126 · Cited by 91 · see citing works

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

Hamuryudan, V., Mat, C., Saip, S., et al. (1998) · Annals of Internal Medicine · Cited by 91 · see citing works

Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies

Kumar, S. K., Witzig, T. E., & Rajkumar, S. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.127 · Cited by 87 · see citing works

Thalidomide Stimulates T Cell Responses and Interleukin 12 Production in HIV-Infected Patients

Haslett, P. A. J., Klausner, J. D., Makonkawkeyoon, S., et al. (1999) · AIDS Research and Human Retroviruses · doi:10.1089/088922299310269 · Cited by 86 · see citing works

BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia

Coleman, M., Leonard, J. P., Lyons, L., Pekle, K. A., Nahum, K., Pearse, R. N., Niesvizky, R., & Michaeli, J. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000006303 · Cited by 78 · see citing works

Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009)

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A. R., Stadtmauer, E. A., Yu, Z., Olesnyckyj, M., Zeldis, J. B., & Knight, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7521 · Cited by 73 · see citing works

An Internally-controlled Double Blind Trial of Thalidomide in Severe Erythema Nodosum Leprosum

WATERS, M. F. R. (1971) · Leprosy Review · doi:10.5935/0305-7518.19710004 · Cited by 64 · see citing works

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives

Musto, P. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.08.007 · Cited by 60 · see citing works

Thalidomide: A novel template for anticancer drugs

Stirling, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90032-6 · Cited by 50 · see citing works

A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies

Bouscary, D., Legros, L., Tulliez, M., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05817.x · Cited by 48 · see citing works

Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma

Srkalović, G., Elson, P. J., Trebisky, B., Karam, M. A., & Hussein, M. A. (2002) · Medical Oncology · doi:10.1385/mo:19:4:219 · Cited by 48 · see citing works

Treatment of Moderately Severe Erythema Nodosum Leprosum with Thalidomide - A Double-blind Controlled Trial

Pearson, J. M. H., & VEDAGIRI, M. (1969) · Leprosy Review · doi:10.5935/0305-7518.19690022 · Cited by 45 · see citing works

THALIDOMIDE AND CONGENITAL ABNORMALITIES

Yang, T., Yang, T.-S., & Liang, H.-M. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91347-3 · Cited by 44 · see citing works

Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

List, A. F., Baker, A. F., Green, S., & Bellamy, W. T. (2006) · Cancer Control · doi:10.1177/107327480601304s02 · Cited by 43 · see citing works

Thalidomide therapy in adult patients with myelodysplastic syndrome

Moreno‐Aspitia, A., Colón‐Otero, G., Hoering, A., et al. (2006) · Cancer · doi:10.1002/cncr.22047 · Cited by 38 · see citing works

Chiral inversion of the second generation IMiD™ CC‐4047 (ACTIMID™) in human plasma and phosphate‐buffered saline

Teo, S. K., Chen, Y., Muller, G. W., et al. (2003) · Chirality · doi:10.1002/chir.10221 · Cited by 34 · see citing works

Thalidomide Has 37-Year History

Randall, T. (1990) · JAMA · doi:10.1001/jama.1990.03440110028006 · Cited by 31 · see citing works

THE ROLE OF ADHESION RECEPTORS IN THE PATHOGENESIS OFMULTIPLE MYELOMA

Witzig, T. E. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70116-7 · Cited by 16 · see citing works

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Raza, A., Reeves, J. E., Feldman, E. J., et al. (2006) · Blood · doi:10.1182/blood.v108.11.250.250 · Cited by 13 · see citing works

Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines

Gandhi, A. K., Naziruddin, S., Verhelle, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.6618 · Cited by 10 · see citing works

Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines

Gandhi, A. K., Naziruddin, S., Verhelle, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.6618 · Cited by 5 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works

Drug repositioning for orphan diseases

Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228 · see citing works

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase

An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176 · see citing works

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide

Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89 · see citing works

Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs

Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84 · see citing works

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide

Tateno, S., Iida, M., Fujii, S., Suwa, T., Katayama, M., Tokuyama, H., Yamamoto, J., Ito, T., Sakamoto, S., Handa, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61027-w · Cited by 36 · see citing works

POMALIDOMIDE: A NOVEL PROMISING IMMUNOMODULATORY AGENT IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA

Nandha, R. (2013) · Journal of Drug Discovery and Therapeutics

New Immunomodulatory Drugs in Myeloma

Lacy, M. Q. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0077-y · Cited by 12 · see citing works

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma

Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.83 · Cited by 24 · see citing works

Thalidomide and its analogues in the treatment of Multiple Myeloma

Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 68 · see citing works